Regeneron Pharmaceuticals Inc stock is traded at $930.67, with a volume of 1,383,731. It is down -4.39% in the last 24 hours and up +26.59% over the past month. Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
Previous Close:
$973.36
Open:
$989.90
24h Volume:
1,383,731
Relative Volume:
1.26
Market Cap:
$96.28B
Revenue:
$14.92B
Net Income/Loss:
$4.42B
P/E Ratio:
22.68
EPS:
$41.04
Net Cash Flow:
$3.79B
1W Performance:
+14.44%
1M Performance:
+26.59%
6M Performance:
+31.23%
1Y Performance:
+48.20%
1-Day Range:
$927.42$991.73
1-Week Range:
$839.08$991.73
52-Week Range:
$591.52$991.73
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Name
Regeneron Pharmaceuticals IncSector
HealthcareIndustry
BiotechnologyPhone
(914) 847-7000Address
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS